Effect of Biological Disease Modifying Anti Rheumatic Drug (bDMARD) Treatment on Spinal Fracture Incidence in Patients With Ankylosing Spondylitis (AS)
Overview
- Phase
- Not Applicable
- Intervention
- bDMARD treatment
- Conditions
- Ankylosing Spondylitis
- Sponsor
- Uppsala University
- Enrollment
- 9858
- Primary Endpoint
- Spinal fracture
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
Ankylosing spondylitis (AS) is a rheumatoid disease affecting all segments of the axial skeleton, leading to the complete fusion of all spinal segments - the bamboo-spine. During the last decade biological disease modifying anti-rheumatic drugs (bDMARD) have been successfully introduced to reduce the disease activity. It is unclear whether bDMARD treatment had an effect on spinal fracture risk related to AS. This national registry study will investigate the effect of bDMARD treatment on spinal fracture risk in a national cohort of patients with AS.
Investigators
Eligibility Criteria
Inclusion Criteria
- •age 30-60 years
- •registered diagnosis of ankylosing spondylitis
Exclusion Criteria
- •age \<30 or \>60 years
Arms & Interventions
AS patients
Patients registered in the Swedish Patient Registry with active AS treated with or without biological DMARD according to the Swedish Prescribed Drugs Registry, with or without spinal fractures
Intervention: bDMARD treatment
Outcomes
Primary Outcomes
Spinal fracture
Time Frame: 10 years
Censored data with occurrence of spinal fracture within 10 years observation